Handelsbanken Fonder AB Takes $642,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Handelsbanken Fonder AB bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 12,000 shares of the company's stock, valued at approximately $642,000.

Other large investors have also added to or reduced their stakes in the company. Plato Investment Management Ltd lifted its position in shares of Janux Therapeutics by 18.7% in the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after purchasing an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $139,000. Chicago Capital LLC bought a new position in shares of Janux Therapeutics during the 4th quarter worth $230,000. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Janux Therapeutics in the third quarter valued at approximately $239,000. Institutional investors own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on JANX shares. Leerink Partners raised their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research report on Tuesday, December 3rd. Leerink Partnrs raised shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $88.00.

Remove Ads

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the business's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the completion of the transaction, the chief executive officer now owns 217,054 shares of the company's stock, valued at approximately $12,196,264.26. This trade represents a 10.33 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Up 5.0 %

Shares of NASDAQ JANX traded up $1.51 during trading hours on Wednesday, hitting $31.50. 1,499,313 shares of the stock were exchanged, compared to its average volume of 813,875. Janux Therapeutics, Inc. has a 12 month low of $29.63 and a 12 month high of $71.71. The firm has a fifty day moving average price of $42.23 and a 200-day moving average price of $47.67. The company has a market cap of $1.65 billion, a PE ratio of -26.92 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.